T
Theseus Pharmaceuticals
Developing best-in-class kinase inhibitors to shape the future of targeted oncology
About Theseus Pharmaceuticals
Theseus Pharmaceuticals is dedicated to revolutionizing cancer treatment by developing next-generation tyrosine kinase inhibitors (TKIs). These inhibitors are designed to target and inhibit all major cancer-causing and drug-resistant mutations in clinically significant tyrosine kinase targets. The company primarily serves cancer patients who are facing treatment resistance, a critical challenge in current cancer therapies. Operating in the biotechnology and pharmaceutical market, Theseus Pharmaceuticals employs a research-driven business model, focusing on the development and commercialization of innovative cancer treatments. Revenue is generated through the development and potential future sales of their proprietary TKIs, as well as possible partnerships and licensing agreements with larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2017
- Headquarters
- Cambridge, United States
- Listing
- IPO 2021
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 69.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2023 | $0 | — | Concentra Biosciences | ↗ |
| POST IPO EQUITYOther financing | Jul 2023 | $0 | — | OrbiMed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$54M | — |
| 2025 | $0 | — | −$54M | — |
| 2024 | $0 | — | −$54M | — |
| 2023 | $0 | — | −$54M | — |
| 2022 | $0 | — | −$54M | — |
| 2021 | $0 | — | −$27M | — |
| 2020 | $0 | — | −$6.8M | — |
Growth signals
Latest recorded traffic for Theseus Pharmaceuticals is 230 monthly website visits, down 86.5% over the last three months. Theseus Pharmaceuticals's team declined 19.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
ARIAD Pharmaceuticals
OrbiMed
Foresite Capital
Adage Capital
Rock Springs Capital
Pontifax Funds
Longitude Capital
Nextech Ventures
T. Rowe Price
Farallon Capital Management
Omega Healthcare Investors
Boxer Capital
Other known investors1 additional known investor
- CBConcentra Biosciences
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Theseus Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Theseus Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.